SCC244 Appears Durable and Efficacious in METex14 Skipping–Positive NSCLC

Patients with non–small cell lung cancer harboring a MET exon 14 skipping mutation appeared to derive durable efficacy following treatment with SCC244.

Treatment with SCC244 yielded robust and long-lasting efficacy in patients with MET exon 14 skipping (METex14)–mutated non–small cell lung cancer, according to findings from the phase 1/2 GLORY study (NCT04270591) that were presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

Overall, patients who received SCC244 demonstrated an overall response rate (ORR) of 60.9% (95% CI, 48.4%-72.4%). Those who were treatment-naïve and previously treated experienced ORRs of 66.7% (95% CI, 50.5%-80.4%) and 51.9% (95% CI, 31.9%-71.3%), respectively. The disease control rate (DCR) across all 3 groups was 82.6% (95% CI, 71.6%-90.7%), 88.1% (95% CI, 74.4%-96.0%), and 74.1% (95% CI, 53.7%-88.9%), respectively. The median duration of response (DOR) was not evaluable (NE) (95% CI, NE-NE) in the treatment-naïve arm and was 5.1 months (95% CI, 2.8-8.2) and 8.2 months (95% CI, 4.8-NE) in the previously treated and overall populations, respectively. In the overall population, 71% of tumor responses were ongoing and investigators reported the potential for DOR to expand.

“The GLORY study demonstrated a high [and durable] efficacy for SCC244. Statistical hypothesis was achieved. Preliminary efficacy on brain metastases was [also] observed,” according to lead author Shun Lu, MD, PhD, a professor at Shanghai Chest Hospital, Jiao Tong University, and chief of Shanghai Lung Cancer Center.

SCC244 is a high selective MET inhibitor that can be taken orally. The multicenter, single-arm, open-label study aimed to assess a primary end point of ORR by blinded independent review committee. Secondary end points included investigator-assessed ORR, DOR, DCR, time to response (TTR), progression-free survival (PFS), 6-month PFS rate, and overall survival (OS).

Patients were required to have locally advanced or metastatic disease with a METexon14 skipping mutation. Moreover, individuals could not have received more than 2 previous systemic therapies or have not received any systemic therapies entirely. SCC244 was administered at a dose of 300 mg until disease progression or intolerance to toxicity or death.

In total, 163 patients were screened, 73 of whom were enrolled on the trial and underwent treatment. Of these patients, 36 stopped treatment due to adverse events (AEs; 11.0%), progressive disease (RECIST, 20.5%; clinical judgement, 1.4%), voluntary withdrawal (12.3%), death (1.2%), or other reasons (2.5%). Treatment is ongoing in 37 patients.

In the overall population, most patients were male (56.2%) with a median age of 69.0 years. Nearly all patients were from China (90.4%), although some were from Japan (9.6%). Most patients were either never smokers (58.9%) or had quit smoking (38.4%), and 94.5% had an ECOG performance status of 1. Notably, 87.7% of patients had locally advanced disease, 74.0% had adenocarcinoma, and 13.7% had brain metastases.

Investigators also reported that 58.9% of patients were untreated, 35.6% had previously received 1 prior line of therapy, 4.1% had 2 prior lines, and 1.4% had 3 prior lines or more. Most patients previously received prior chemotherapy (38.4%), immunotherapy (11.0%), targeted therapy (5.5%), or traditional Chinese medicine (4.1%).

In terms of SCC244’s efficacy for brain metastases, the agent yielded 8 partial responses in 10 patients. Targeted brain metastases were reduced by 30% in 5 patients. The median TTR was 1.4 months.

After a median follow-up of 5.6 months, the median PFS was NE (95% CI, 4.3-NE) in the treatment-naïve arm, 5.7 months (95% CI, 2.8-7.6) in the previously treated arm, and 7.6 months (95% CI, 4.2-NE) in the overall population.

In terms of safety, investigators reported that 97.3% of treatment-emergent AEs (TEAEs) were related to the study drug. Serious TEAEs occurred in 27.4% of patients and 28.8% of TEAEs led to dose interruptions. Additionally, 28.8% and 11.0% of patients required a dose reduction or permanent discontinuation, respectively, due to TEAEs. The most common any grade treatment-related AEs (TRAEs) included oedema peripheral (75.3%), headache (32.9%), and nausea (27.4%), with grade 3 or higher TRAEs including oedema peripheral (19.2%), neutropenia (4.1%) and rash (2.7%).


Lu S, Yu Y, Zhou J, et al. Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study) Presented at: 2022 AACR Annual Meeting; April 8-13, 2022; New Orleans, LA. Abstract CT034.

Related Videos
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Related Content